FDA publishes complete response letter rejecting Summit's lung cancer drug
Published 3 d ago1 sourceEvidence: Reported
The FDA has rejected Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy, a decision that had been anticipated given the prolonged review. The rejection is a setback for the company and for patients awaiting a new treatment option, though the specific reasons for the refusal have not been detailed.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 3 d ago1 sourceEvidence: Reported
Published 21 h ago5 sourcesEvidence: Reported
Published 2 d ago4 sourcesEvidence: Reported
Published 16 h ago3 sourcesEvidence: Reported
Published 13 h ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 3 d ago3 sourcesEvidence: Reported